The short version of 三重激动剂 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
=== Africa === In addition to the mummies of Egypt, there have been instances of mummies being discovered in other areas of the African continent. The bodies show a mix of anthropogenic and spontaneous mummification, with some being thousands of years old.
== Further reading == Larsen PR, Williams RL (2003). Williams textbook of endocrinology (10th ed.). Philadelphia: WB Saunders. ISBN 978-0-7216-9184-8. Doppman, John L. (15 August 1995). "Localization of Insulinomas to Regions of the Pancreas by Intra-arterial Stimulation with Calcium". Annals of Internal Medicine. 123 (4): 269–273. doi:10.7326/0003-4819-123-4-199508150-00004. PMID 7611592. S2CID 20993342. Vella, Adrian. "Insulinoma". UpToDate.
While the Midwest almost always makes its lefse with potatoes, this is not necessarily the case in Norway. When one uses the term lefse in the United States, it typically refers to what Norwegians call potato lefse. Norwegians, however, also make Hardangerlefse with egg yolks and buttermilk. The tradition of making lefse was brought over by Norwegian Americans, and potato lefse itself was made when their potato crop was successful. Due to this, it became more prevalent than other types in the United States. When lefse was able to be made, it was stored in small storage buildings called bryggerhus. When Norwegian immigrants first arrived in America, they did not have the usual foods they were used to back home, including milk and porridge, dried meat, and lefse, but early Norwegian-American immigrants brought folded lefse to eat for the beginning stages of their journey via ship. After these were eaten, the lack of food they were used to is likely why they turned back to tradition so quickly. During World War I, Americans were encouraged to eat potatoes to be patriotic, as wheat was needed to feed the troops on the front lines. Lefse, a staple for Norwegian Americans, was eaten with gusto during this time. While lefse is generally not eaten with day-to-day meals in Norway today, Norwegian Americans traditionally give prominence to having lefse with dinner.
=== 2000 census === As of the census of 2000, there were 2,975 people, 1,116 households, and 785 families living in the city. The population density was 1,431.1 inhabitants per square mile (552.6/km2). There were 1,145 housing units at an average density of 550.8 units per square mile (212.7 units/km2). The racial makeup of the city was 98.39% White, 0.20% African American, 0.07% Native American, 0.20% Asian, 0.71% from other races, and 0.44% from two or more races. Hispanic or Latino of any race were 1.34% of the population. There were 1,116 households, out of which 36.9% had children under the age of 18 living with them, 58.1% were married couples living together, 8.6% had a female householder with no husband present, and 29.6% were non-families. 26.3% of all households were made up of individuals, and 16.6% had someone living alone who was 65 years of age or older. The average household size was 2.56 and the average family size was 3.11. In the city, the population was spread out, with 27.8% under the age of 18, 7.2% from 18 to 24, 26.6% from 25 to 44, 17.4% from 45 to 64, and 21.0% who were 65 years of age or older. The median age was 37 years. For every 100 females, there were 89.7 males. For every 100 females age 18 and over, there were 84.2 males. The median income for a household in the city was $37,500, and the median income for a family was $50,268. Males had a median income of $32,225 versus $23,500 for females. The per capita income for the city was $18,308.
== Use as a biochemical marker for bone formation == As osteoblasts produce osteocalcin, it is often used as a marker for the bone formation process. Higher serum osteocalcin levels have been observed to correlate relatively well with increases in bone mineral density during treatment with anabolic bone formation drugs for osteoporosis, such as teriparatide. In many studies, osteocalcin is used as a preliminary biomarker for the effectiveness of a given drug on bone formation. For instance, one study that aimed to study the efficacy of a glycoprotein called lactoferrin on bone formation used osteocalcin to measure osteoblast activity.
Sources: en.wikipedia.org
Low-boiling perfluoroalkanes are potent greenhouse gases, in part due to their very long atmospheric lifetime, and their use is covered by the Kyoto Protocol. The global warming potential (compared to that of carbon dioxide) of many gases can be found in the IPCC 5th assessment report, with an extract below for a few perfluoroalkanes.
When the upper plate was connected to the negative pole of the battery and the lower plate to the positive pole, the glowing patch moved downwards, and when the polarity was reversed, the patch moved upwards.
The amine intermediate was treated with benzoyl chloride and ammonium thiocyanate followed by alkaline hydrolysis to form a thiourea. This was activated as its isothiuronium salt before being treated with ethylene diamine to give tizanidine.
{\displaystyle Q=\left[m_{\text{N}}\left({\ce {^{\mathit {A}}_{\mathit {Z}}X}}\right)-m_{\text{N}}\left({\ce {^{\mathit {A}}_{{\mathit {Z}}+1}X'}}\right)-m_{\text{e}}-m_{{\overline {\nu }}_{\text{e}}}\right]c^{2}}
Sources: en.wikipedia.org
Abnormally high levels of homocysteine in the serum, above 15 μmol/L, are a medical condition called hyperhomocysteinemia. This has been claimed to be a significant risk factor for the development of a wide range of diseases, in total more than 100 including thrombosis, neuropsychiatric illness, in particular dementia and fractures. It also is found to be associated with microalbuminuria (moderately increased albuminuria), which is a strong indicator of the risk of future cardiovascular disease and renal dysfunction. Vitamin B12 deficiency, even when coupled with high serum folate levels, has been found to increase overall homocysteine concentrations as well. Typically, hyperhomocysteinemia is managed with vitamin B6, vitamin B9, and vitamin B12 supplementation. However, supplementation with these vitamins does not appear to improve cardiovascular disease outcomes. An important consideration when specifically supplementing with folic acid (vitamin B9) is to use a lower dosage. Over-supplementation with folic acid may produce negative health effects, including increased risk of cardiovascular disease and the development of cancer. It has been shown that the ideal dose of folic acid for lowering homocysteine levels is up to 1.2 mg per day. Higher dosages do not result in a greater decrease of homocysteine levels in the general population, which excludes individuals with certain mutations in the MTHFR gene. Certain mutations in the MTR, MTHFR, and MTRR enzymes can cause hyperhomocysteinemia.
The Communist Labor Party of the United States of North America (CLP or CLP(USNA)) was an anti-revisionist communist party that was part of the New Communist movement in the United States. The CLP was founded in 1974 and disbanded in 1993. The League of Revolutionaries for a New America was then founded by CLP members. During its lifetime, the CLP was frequently critical of the US Communist Party and the Soviet Union and refused to become closely aligned with other foreign communist parties. Established as a traditional industrial union party, the CLP began to reexamine its focus as the industrial workforce in the United States started declining in the 1980s. By 1993, CLP members had decided that the party could no longer grow in its present form and decided to disband it.
=== Dietary intake === The Dietary Reference Intake (DRI) Recommended Daily Amount (RDA) for vitamin A for a 25-year-old male is 900 micrograms/day, or 3000 IU. National Health Service daily recommended values are slightly lower at 700 micrograms for men and 600 micrograms for women. During the absorption process in the intestines, retinol is incorporated into chylomicrons as the ester form, and it is these particles that mediate transport to the liver. Liver cells store vitamin A as the ester, and when retinol is needed in other tissues, it is de-esterifed and released into the blood as the alcohol. Retinol then attaches to a serum carrier, retinol binding protein, for transport to target tissues. A binding protein inside cells, cellular retinoic acid binding protein, serves to store and move retinoic acid intracellularly.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.